Civil War commemoration ceremony to take place April 12
in observance of anniversary of firing on Fort Sumter

A SOLEMN HISTORY

By LUI STANFORD

S

THE VILLAGES -

The Civil War commemoration ceremony will take place at 10 a.m. Wednesday at the outskirts of the town of al-Agila, Libya.

The Associated Press

LIBYAN REBELS
LOSE GROUND,
PLEAD FOR HELP

The Associated Press

LIBYAN REBELS
LOSE GROUND,
PLEAD FOR HELP

By RYAN LUCAS

WASHINGTON - Medicare officials said Wednesday that the program will pay the $100,000 cost of prostate cancer treatment for patients 65 or older. Several months of active treatment, along with an array of others.

The Associated Press

The Villages
USF'S HEALTH CARE LEADERS EXCITED
ABOUT PARTNERSHIP WITH VILLAGES

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By MATTHEW PERRONE

WASHINGTON - The Associated Press

MEDICARE OFFICIALS said Wednesday that the program will pay the $100,000 cost of prostate cancer treatment for patients 65 or older, several months of treatment, along with an array of others.

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a clip.

By CURT HILLS

THE VILLAGES - The announcement of a five-year health care agreement between an area hospital system and an area health network may be creating chatter now, but its organizational behavior will develop at a cli


DRUG, from A1

Provenge is the latest and most innovative cancer drug to be approved by the Food and Drug Administration, but what's the impact on drug pricing and the US health care system?

Since its approval in 2009, Provenge has been the focus of intense debate among government health care leaders and the medical community.

The drug, which is used to treat men with localized or locally advanced prostate cancer, has been controversial due to its high cost and lack of proven efficacy.

Despite its high price tag, Provenge has been hailed as a breakthrough treatment for an incurable disease.

But many experts say the drug is not worth the cost, as it has little impact on survival rates and can cause severe side effects.

The drug's development has sparked a national conversation about the cost of cancer treatments and the need for more affordable options.

In response to the controversy, several alternative therapies have been proposed, including personalized immunotherapy and targeted therapies.

These options may offer more targeted treatments and potentially lower costs.

But many experts agree that more research is needed to determine the efficacy and cost-effectiveness of these alternative therapies.

As the debate continues, it's clear that finding an affordable and effective treatment for prostate cancer remains a priority for both patients and the medical community.

The challenge is to balance patient needs with the need to contain costs — a challenge that will likely continue to be a focus of attention in the years to come.